CA3030930A1 - Analogues de l'insuline - Google Patents

Analogues de l'insuline Download PDF

Info

Publication number
CA3030930A1
CA3030930A1 CA3030930A CA3030930A CA3030930A1 CA 3030930 A1 CA3030930 A1 CA 3030930A1 CA 3030930 A CA3030930 A CA 3030930A CA 3030930 A CA3030930 A CA 3030930A CA 3030930 A1 CA3030930 A1 CA 3030930A1
Authority
CA
Canada
Prior art keywords
absent
leu
val
glu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3030930A
Other languages
English (en)
Inventor
John Gerbrandt Tasman Menting
Brian Smith
Danny Hung-Chieh Chou
Helena SAFAVI-HEMAMI
Michael Colin Lawrence
Olivera M. BALDOMERO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Walter and Eliza Hall Institute of Medical Research
University of Utah Research Foundation UURF
Original Assignee
Walter and Eliza Hall Institute of Medical Research
University of Utah Research Foundation UURF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016902883A external-priority patent/AU2016902883A0/en
Application filed by Walter and Eliza Hall Institute of Medical Research, University of Utah Research Foundation UURF filed Critical Walter and Eliza Hall Institute of Medical Research
Publication of CA3030930A1 publication Critical patent/CA3030930A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C30B29/58—Macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/02—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des analogues de l'insuline, en particulier des analogues de l'insuline présentant des chaînes B raccourcies. La présente invention concerne également la structure cristalline de l'insuline provenant du venin d'escargots marins, ainsi que des procédés d'utilisation du cristal et des informations structurales associées pour cribler et concevoir des analogues d'insuline qui interagissent avec ou modulent le récepteur de l'insuline. La présente invention concerne également des procédés thérapeutiques et prophylactiques utilisant les analogues de l'insuline.
CA3030930A 2016-07-22 2017-07-21 Analogues de l'insuline Pending CA3030930A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2016902883A AU2016902883A0 (en) 2016-07-22 Insulin Analogs
AU2016902883 2016-07-22
US201762483118P 2017-04-07 2017-04-07
US62/483,118 2017-04-07
PCT/AU2017/050758 WO2018014091A1 (fr) 2016-07-22 2017-07-21 Analogues de l'insuline

Publications (1)

Publication Number Publication Date
CA3030930A1 true CA3030930A1 (fr) 2018-01-25

Family

ID=60991677

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3030930A Pending CA3030930A1 (fr) 2016-07-22 2017-07-21 Analogues de l'insuline

Country Status (3)

Country Link
AU (1) AU2017298565B2 (fr)
CA (1) CA3030930A1 (fr)
WO (1) WO2018014091A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3481945A4 (fr) 2016-07-11 2020-07-29 Board of Regents, The University of Texas System Polypeptides de recombinaison comprenant de la sélénocystéine et leur procédé de production
MA45727A (fr) 2016-07-22 2019-05-29 Walter & Eliza Hall Inst Medical Res Analogues de l'insuline
JP7186400B2 (ja) 2016-08-30 2022-12-09 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ゲノム的に再コードした生物におけるセレノ－生物製剤の製造
WO2018187568A1 (fr) * 2017-04-07 2018-10-11 University Of Utah Research Foundation Analogues d'insuline et procédés d'utilisation
LT3892628T (lt) * 2018-06-29 2022-12-12 Akston Biosciences Corporation Itin ilgai veikiantys insulino-fc sulieti baltymai ir naudojimo būdai
CN114675019B (zh) * 2022-02-10 2022-12-16 江苏省人民医院（南京医科大学第一附属医院） 一种检测胰岛素受体胞外段抗体的试剂盒

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095443A1 (fr) * 2004-03-31 2005-10-13 Cardio Incorporated Système d'administration médicamenteuse utilisant un peptide modifié
US7790677B2 (en) * 2006-12-13 2010-09-07 Elona Biotechnologies Insulin production methods and pro-insulin constructs
CN103889443A (zh) * 2011-06-17 2014-06-25 哈洛齐梅公司 使用透明质酸降解酶的持续皮下胰岛素输注法

Also Published As

Publication number Publication date
AU2017298565B2 (en) 2021-08-19
AU2017298565A1 (en) 2019-02-21
WO2018014091A1 (fr) 2018-01-25

Similar Documents

Publication Publication Date Title
AU2017298565B2 (en) Insulin analogs
Pioszak et al. Molecular recognition of corticotropin-releasing factor by its G-protein-coupled receptor CRFR1
US7225083B2 (en) Crystallographic structure of the androgen receptor ligand binding domain
US8377701B2 (en) Specific ligands to sortilin
EP2411038B1 (fr) Peptides de l'hormone parathyroïdienne et peptides de la protéine apparentée à l'hormone parathyroïdienne ainsi que des procédés d'utilisation
AU2021269301B2 (en) Insulin Analogs
EP2901154B1 (fr) Structure d'insuline dans un complexe avec des régions terminales en n et en c de la chaîne alpha du récepteur de l'insuline
Kosinová et al. Insight into the structural and biological relevance of the T/R transition of the N-terminus of the B-chain in human insulin
US20100248974A1 (en) Crystal structure of cd147 extracellular region and use thereof
Seow et al. Structure and characterisation of a key epitope in the conserved C-terminal domain of the malaria vaccine candidate MSP2
NZ750355B2 (en) Insulin analogs
EP1385885B1 (fr) Fragments du recepteur orphelin apparente aux recepteurs de l'acide retinoique (ror) comportant le domaine de liason aux ligands (lbd), la structure cristalline du lbd du ror-beta, et leurs applications
EP1265927B1 (fr) Cristal
Žáková et al. Toward the Insulin− IGF-I Intermediate Structures: Functional and Structural Properties of the [TyrB25NMePheB26] Insulin Mutant
Erskine et al. Structure of the neuronal protein calexcitin suggests a mode of interaction in signalling pathways of learning and memory
Watson Insulin analogues for insulin receptor studies and medical applications

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220505

EEER Examination request

Effective date: 20220505

EEER Examination request

Effective date: 20220505

EEER Examination request

Effective date: 20220505

EEER Examination request

Effective date: 20220505